Delivery Order SPE2DR25D2006-SPE2DR26F55VZ
- Not listed
- The Defense Logistics Agency awarded a $21,626.20 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This firm fixed-price delivery order, with an ultimate completion date of September 2, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL auto-injector pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded a $4,430.83 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. The contract specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 24, 2025. This delivery order was competitively awarded with no set-aside designation and represents a child contract under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,906.05 on September 22, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order will be fulfilled from the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $6,690.93 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 ml auto-injector pens. The contract was awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, and employs firm fixed price terms with no set-aside designation. Performance will take place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a $11,794.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 8, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This competitively awarded contract, with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $2,877.84 delivery order to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 mL auto-injector pens on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be fulfilled at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery order issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors with a ceiling value of $4,575.76. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The award is issued from the company's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of November 5, 2025. This delivery order...
- The Defense Logistics Agency awarded a $2,287.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector units. The contract, which carries an ultimate completion date of October 17, 2025, represents a non-set-aside competitive award with performance to be executed at the vendor's Conshohocken, Pennsylvania location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $15,757.28 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. The contract, awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- SPE2DR25D2006Indefinite Delivery Contract
- SPE2DR25D2006-SPE2DR26F55VZDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector pens, with a ceiling value of $1,205.54 and a firm fixed price structure. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of November 4, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 prime vendor vehicle valued through December 2026 that supports pharmaceutical supply needs across military and federal healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly through the Defense Logistics Agency's medical supply chain. The company's federal contract portfolio demonstrates extensive capability in supplying brand-name and generic pharmaceuticals, specialty medications, vaccines, and medical devices across multiple therapeutic domains. This delivery order for Actemra, a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory conditions, represents part of the company's ongoing support for military healthcare programs and the Defense Health Agency.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 11/3/25 |